Wright Cheryl L, Stewart Ian D
Surgical Pathology Unit, North Shore Hospital, Takapuna, Auckland, New Zealand.
Am J Surg Pathol. 2003 Nov;27(11):1393-406. doi: 10.1097/00000478-200311000-00001.
Defects in the mismatch repair (MMR) genes hMLH1 and hMSH2 have been found in 10% to 20% of sporadic colorectal carcinomas and also many cases of hereditary nonpolyposis colorectal cancer syndrome. Patients with these tumors have an improved prognosis and may show greater sensitivity to chemotherapy. We examined 458 resected colorectal carcinomas from 430 consecutive patients and used immunohistochemistry to determine which tumors lacked expression of these genes (MMR-d). We correlated the status of MMR-d or "intact" expression with stage, site, and histology. Eighty-nine of 458 tumors (19.4%) were MMR-d, including 80 hMLH1 and 9 hMSH2 tumors. A total of 6% of patients had synchronous tumors, and 37.7% of these were MMR-d (P=0.0008). A high proportion of patients with previous breast cancer (4 of 6 patients) had hMLH1-defective colorectal carcinomas. MMR-d tumors presented at an earlier stage than intact tumors, and the node-positive MMR-d tumors were less likely than intact tumors to have pericolonic extranodal tumor deposits (18.2% vs. 44%). The proportion of tumors at each site that were MMR-d increased progressively from cecum (32%) to ascending (35%) to transverse colon, where 41% of all tumors were defective. The proportions then rapidly decreased, reaching the lowest rate (4.7%) in the rectum. Both types of MMR-d tumors more often had expansive borders, intraepithelial lymphocytosis, peritumoral lymphoid, and Crohn's-like lymphoid responses than the intact tumors; the frequencies of these features diminished with advancing stage. Tumor budding was less common in stage II and III MMR-d tumors than in intact tumors. Keloid and myxoid type stromas correlated with stage and vascular invasion and were not related to mismatch repair status. Significant differences existed between the hMLH1 and hMSH2 tumors. The reported right-sided preponderance of MMR-d tumors is due to most hMLH1, but not hMSH2, tumors being found there (87.5% vs. 44.4%). hMSH2 tumors were most common in the rectum (55.6%). Mucinous tumors were common in hMLH1 tumors (36.3%) but not in hMSH2 tumors (11.1%). hMLH1 tumors were most likely to be poorly differentiated (70%), which was uncommon with hMSH2 tumors (22.2%). hMSH2 tumors were more likely to be confined to the wall (66.7%) than hMLH1 (20%) or intact tumors (23%). We conclude that hMLH1 and hMSH2-defective tumors have distinctly differing histologic features from each other.
错配修复(MMR)基因hMLH1和hMSH2的缺陷在10%至20%的散发性结直肠癌以及许多遗传性非息肉病性结直肠癌综合征病例中被发现。患有这些肿瘤的患者预后有所改善,并且可能对化疗表现出更高的敏感性。我们检查了来自430例连续患者的458例切除的结直肠癌,并使用免疫组织化学来确定哪些肿瘤缺乏这些基因的表达(错配修复缺陷,MMR-d)。我们将MMR-d或“完整”表达状态与分期、部位和组织学进行了关联。458例肿瘤中有89例(19.4%)为MMR-d,包括80例hMLH1缺陷型肿瘤和9例hMSH2缺陷型肿瘤。共有6%的患者有同步性肿瘤,其中37.7%为MMR-d(P = 0.0008)。既往有乳腺癌的患者中很大一部分(6例中的4例)患有hMLH1缺陷型结直肠癌。MMR-d肿瘤比完整肿瘤出现的分期更早,并且淋巴结阳性的MMR-d肿瘤比完整肿瘤更不容易出现结肠旁结外肿瘤沉积(18.2%对44%)。MMR-d肿瘤在各个部位的比例从盲肠(32%)到升结肠(35%)再到横结肠逐渐增加,横结肠中所有肿瘤的41%存在缺陷。然后比例迅速下降,在直肠中达到最低率(4.7%)。与完整肿瘤相比,两种类型的MMR-d肿瘤更常具有边界扩展、上皮内淋巴细胞增多、肿瘤周围淋巴细胞浸润以及克罗恩样淋巴细胞反应;这些特征的频率随着分期进展而降低。在II期和III期MMR-d肿瘤中,肿瘤芽生比完整肿瘤少见。瘢痕疙瘩样和黏液样间质与分期和血管侵犯相关,与错配修复状态无关。hMLH1和hMSH2肿瘤之间存在显著差异。报告中MMR-d肿瘤右侧优势是由于大多数hMLH1肿瘤(而非hMSH2肿瘤)在右侧被发现(87.5%对44.4%)。hMSH2肿瘤在直肠中最为常见(55.6%)。黏液性肿瘤在hMLH1肿瘤中常见(36.3%),但在hMSH2肿瘤中不常见(11.1%)。hMLH1肿瘤最有可能分化差(70%),而这在hMSH2肿瘤中不常见(22.2%)。与hMLH1肿瘤(20%)或完整肿瘤(23%)相比